An outside-in read of the real-world-data field, written before I started. Below is what I've come to think — held loosely — and the notes behind each one. The map is one way to picture where the competitors actually sit, and where Inovalon's data looks genuinely hard to copy. Starting points for conversations with the team, not settled answers.
Not clinical depth, not raw breadth — those spaces are already held. Every major rival cedes this one, because of how each is built.
Directional 02HEOR and market access is a multi-billion category — roughly $2–4B now, $8–13B by 2030. The payer-grade slice is a real fraction of that, not a $100M niche.
Directional · sizing rough 03US-native EHR, AI-native. The one place Inovalon is clearly behind is AI. That's the gap to close.
Fairly confident 04Optum is the only other payer-native player, but UnitedHealth ownership makes its neutrality suspect. And HealthVerity resells Inovalon's data — a distributor turning into a rival, where Inovalon still holds the source.
Fairly confident on the structureEach is a starting point, not a verdict — the link goes to the notes underneath it. The most speculative is 01, and it's the one I'd most want to pressure-test.
The top-right is payer-native and productized — where Inovalon sits. The only neighbor in it is Optum, and being owned by UnitedHealth makes its neutrality a hard sell to payers and pharma alike. The capable players on the left — IQVIA, Truveta, the oncology specialists — are formidable, but structurally pointed at pharma, not the payer side. So the real question isn't "is the space empty." It's "can a neutral player hold it." Each dot links to my notes.
A competitive map is supply-side — whose data is whose. The demand side decides what's worth building. Here the buyer splits, and pitching the wrong layer is the classic enterprise-RWD stall.
Runs the analysis and feels the pain — but rarely holds the budget.
Owns the spend. Often a step removed from the day-to-day use case.
Sell the layer that feels the pain to the layer that signs the check, or it dies in procurement.
Sells to pharma and payers — the position IQVIA and Truveta can't both claim.
Every read in one place, sorted by how close each sits to Inovalon's lane — the synthesis up top, then the four I dug into, then a lighter sweep of the rest. Threat means threat to the payer-native wedge. Each row links to its write-up.
| Tier | Company | Threat | Reports | One-line read | Latest pull |
|---|---|---|---|---|---|
| Synthesis | Inovalon | — | Synthesis | Where it has room, how big it is, who pays, and the one place it's behind. | Jun 18 |
| Background | Deep Research | — | Read | Inovalon and the landscape it sits in. | Jun 11 |
| Deep dive | Optum | High | Teardown·CI | Only other payer-native player; UNH ownership and a pharma-RWD AI vacuum keep the flank open. | Jun 21 |
| Deep dive | Truveta | Med-High ↑ | Teardown·CI | Provider-owned US EHR, AI-native — exposes the AI gap. | Jun 13 |
| Deep dive | IQVIA | Medium | Teardown·CI | Global regulatory-grade RWE; cedes the payer-native space. | Jun 13 |
| Deep dive | HealthVerity | Medium | Teardown·CI | Marketplace that resells Inovalon's data — we hold the source. | Jun 16 |
| Sweep | Datavant | High ↑ | CI | Tokenization standard pushing into RWE + risk adjustment. | Jun 13 |
| Sweep | Epic Cosmos | Indirect ↑ | CI | Largest US clinical corpus + its own model — can't be bought. | Jun 19 |
| Sweep | Flatiron | Locked | CI | Regulatory-grade oncology, Roche-owned; one therapeutic area. | Jun 13 |
| Sweep | Tempus | Locked | CI | Lab-anchored oncology clinico-genomics, sold via Lens. | Jun 13 |
| Sweep | ConcertAI | Locked | CI | Neutral oncology + agentic AI; CEO is Inovalon's ex-president. | Jun 13 |
Worth flagging: Datavant is now the highest-threat company with the lightest analysis — the one I'd deepen next.